Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 6,214 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $22.15, for a total value of $137,640.10. Following the completion of the transaction, the insider owned 21,479 shares in the company, valued at $475,759.85. The trade was a 22.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock traded down $0.79 during trading hours on Monday, hitting $19.04. The company’s stock had a trading volume of 485,721 shares, compared to its average volume of 397,280. The business has a 50 day moving average price of $25.41 and a two-hundred day moving average price of $32.15. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $44.28. The company has a market cap of $577.48 million, a PE ratio of -43.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49). The business had revenue of $84.23 million for the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. Analysts expect that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Large investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC bought a new stake in Castle Biosciences during the third quarter worth approximately $16,105,000. Campbell & CO Investment Adviser LLC bought a new stake in Castle Biosciences during the third quarter worth approximately $615,000. Portolan Capital Management LLC increased its stake in Castle Biosciences by 1.7% during the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock worth $34,499,000 after acquiring an additional 25,539 shares during the last quarter. SG Americas Securities LLC bought a new stake in Castle Biosciences during the third quarter worth approximately $297,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Castle Biosciences during the third quarter worth approximately $667,000. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. KeyCorp reiterated an “overweight” rating and issued a $50.00 target price on shares of Castle Biosciences in a research report on Thursday, January 29th. Lake Street Capital boosted their target price on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Robert W. Baird decreased their target price on Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a research report on Thursday. Wall Street Zen downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Castle Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $46.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.